标题
Mutational and biophysical robustness in a pre-stabilized monobody
作者
关键词
consensus design, stability–function trade-off, loop grafting, mini proteins, monobodies, adnectin, non-antibody scaffold, fibronectin
出版物
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume -, Issue -, Pages 100447
出版商
Elsevier BV
发表日期
2021-02-25
DOI
10.1016/j.jbc.2021.100447
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Miniproteins as a Powerful Modality in Drug Development
- (2020) Zachary R. Crook et al. TRENDS IN BIOCHEMICAL SCIENCES
- Design Strategy to Create Antibody Mimetics Harbouring Immobilised Complementarity Determining Region Peptides for Practical Use
- (2020) Tetsuya Kadonosono et al. Scientific Reports
- Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
- (2020) Peter G. Chandler et al. Cells
- Reconstitution of an Anti‐HER2 Antibody Paratope by Grafting Dual CDR‐Derived Peptides onto a Small Protein Scaffold
- (2020) Kyra See et al. Biotechnology Journal
- Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy
- (2020) Mahendra P. Deonarain et al. Expert Opinion on Drug Discovery
- Spectroscopic Evidence of the Salt-Induced Conformational Change around the Localized Electric Charges on the Protein Surface of Fibronectin Type III
- (2020) Chikashi Ota et al. LANGMUIR
- Selection enhances protein evolvability by increasing mutational robustness and foldability
- (2020) Jia Zheng et al. SCIENCE
- Protein engineering: the potential of remote mutations
- (2019) Matthew Wilding et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Consensus sequence design as a general strategy to create hyperstable, biologically active proteins
- (2019) Matt Sternke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
- (2019) Jodi L. Karnell et al. Science Translational Medicine
- Advances in liquid formulations of parenteral therapeutic proteins
- (2019) Robert J. Falconer BIOTECHNOLOGY ADVANCES
- Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
- (2019) E. Stein et al. ATHEROSCLEROSIS
- GSK3732394: a Multi-specific Inhibitor of HIV Entry
- (2019) David Wensel et al. JOURNAL OF VIROLOGY
- Directed evolution methods for overcoming trade‐offs between protein activity and stability
- (2019) Samuel D. Stimple et al. AICHE JOURNAL
- Principles of Protein Stability and Their Application in Computational Design
- (2018) Adi Goldenzweig et al. Annual Review of Biochemistry
- The direction of protein evolution is destined by the stability
- (2018) Natsuko Ota et al. BIOCHIMIE
- Conformational dynamics and enzyme evolution
- (2018) Dušan Petrović et al. Journal of the Royal Society Interface
- Abstract CT130: Clinical trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T cells in relapsed/refractory (r/r) multiple myeloma (MM)
- (2018) Tara K. Gregory et al. CANCER RESEARCH
- Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function
- (2018) S -Y Lau et al. PROTEIN ENGINEERING DESIGN & SELECTION
- A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1 : Validation in Mouse Models and Human Cancer Tissues
- (2018) Arutselvan Natarajan et al. CLINICAL CANCER RESEARCH
- Role of Buffers in Protein Formulations
- (2017) Teddy J. Zbacnik et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Biophysical properties of the clinical-stage antibody landscape
- (2017) Tushar Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circumventing the stability-function trade-off in an engineered FN3 domain
- (2016) Benjamin T. Porebski et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Consensus protein design
- (2016) Benjamin T. Porebski et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Engineering long shelf life multi-layer biologically active surfaces on microfluidic devices for point of care applications
- (2016) Waseem Asghar et al. Scientific Reports
- Smoothing a rugged protein folding landscape by sequence-based redesign
- (2016) Benjamin T. Porebski et al. Scientific Reports
- Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
- (2015) Andreas Plückthun Annual Review of Pharmacology and Toxicology
- Challenges and opportunities for non-antibody scaffold drugs
- (2015) Rodrigo Vazquez-Lombardi et al. DRUG DISCOVERY TODAY
- Tolerability of hypertonic injectables
- (2015) Wei Wang INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Controlling protein stability: Mechanisms revealed using formulations of arginine, glycine and guanidinium HCl with three globular proteins
- (2015) Lauren Platts et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Developability Assessment During the Selection of Novel Therapeutic Antibodies
- (2015) Alexander Jarasch et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Structural and dynamic properties that govern the stability of an engineered fibronectin type III domain
- (2015) Benjamin T. Porebski et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Adnectin-Targeted Inhibitors: Rationale and Results
- (2015) Esha Sachdev et al. Current Oncology Reports
- Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
- (2014) David Schiff et al. INVESTIGATIONAL NEW DRUGS
- Effect of Polysorbate 80 Concentration on Thermal and Photostability of a Monoclonal Antibody
- (2012) Meera Agarkhed et al. AAPS PHARMSCITECH
- Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture
- (2012) Maximilian Ackermann et al. ANGIOGENESIS
- CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy
- (2012) J. Dawn Waters et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
- (2011) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- Non-immunoglobulin based protein scaffolds
- (2011) John Löfblom et al. CURRENT OPINION IN BIOTECHNOLOGY
- Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients
- (2011) Robert J Falconer et al. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY
- Interaction of Arginine with Proteins and the Mechanism by Which It Inhibits Aggregation
- (2010) Diwakar Shukla et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2
- (2010) Roni Mamluk et al. mAbs
- Adnectins: engineered target-binding protein therapeutics
- (2010) D. Lipovsek PROTEIN ENGINEERING DESIGN & SELECTION
- Folding of beta-sandwich proteins: Three-state transition of a fibronectin type III module
- (2010) Ernesto Cota et al. PROTEIN SCIENCE
- Stability effects of mutations and protein evolvability
- (2009) Nobuhiko Tokuriki et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Recent trends in stabilising peptides and proteins in pharmaceutical formulation – considerations in the choice of excipients
- (2009) Lene Jorgensen et al. Expert Opinion on Drug Delivery
- Exploring protein fitness landscapes by directed evolution
- (2009) Philip A. Romero et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Protein Dynamism and Evolvability
- (2009) N. Tokuriki et al. SCIENCE
- mRNA Display Selection of a High-Affinity, Modification-Specific Phospho-IκBα-Binding Fibronectin
- (2008) C. Anders Olson et al. ACS Chemical Biology
- The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
- (2008) Sean P Dineen et al. BMC CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now